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It has been shown that rat and human endometria have the
capacity to produce complement component 3 (C3). In rats,
endometrial C3 is an oestrogen-dependent protein produced
and secreted by glandular cells. The cell responsible for the
synthesis and secretion of human endometrial C3 has not been
clearly defined. Our study was aimed at answering this
question. Samples of endometrium obtained from
hysterectomies were either immunostained for C3 or digested
with collagenase; then the stromal and glandular cells were
separated and immunopurified (or not) with an antibody to
CD45 coupled to magnetic beads to eliminate the endometrial
lymphomyeloid cells. Cells were cultured for 2 weeks and C3
measured in the medium by an in-house radioimmunoassay.
Glandular as well as stromal cells stained positively for C3
and released C3 in vitro. The release of C3 from both cell
types could be inhibited by cycloheximide. Epithelial cells
produced significantly more C3 than stromal cells, and
endometrial C3 production was higher for both cell types
when these were obtained from secretory as compared to
proliferative endometria. Lymphomyeloid cells were possibly
a source of C3 since after immunoadsorption of these cells,
the remaining stromal or glandular cells produced
significantly less C3. We conclude that endometrial stromal,
glandular and lymphomyeloid cells all produce C3.
Key words: complement component 3/endometrial cell culture/
endometriosis/intra-uterine device
Introduction
Complement component 3 (C3) is a /32-glycoprotein synthesized
as pro-C3 by hepatocytes (major source), monocytes, fibroblasts
and endothelial cells. It has a molecular mass of 180 kDa and
is composed of two non-identical polypeptide chains (a, 0) held
together by non-covalent interactions.
The a chain and the /3 chain are 110 and 70 kDa in size
respectively (Bokisch et al., 1975). C3 plays a pivotal role in
the process of complement activation. Binding of activated C3
(C3b) to non-self cell surfaces (self surfaces contain molecules
which limit binding of C3b) activates a molecular complex of
several other complement components (C5 — C9) which becomes
capable of osmotic disruption of the invading non-self cells.
Weed and Arquembourg (1980) were the first to report the
presence of complement component 3 (C3) in eutopic endometria
from women suffering from endometriosis. Since they could not
observe C3 in normal endometrium they concluded that
endometriosis was an autoimmune disease. In contrast to this
original observation, several studies have reported the presence
of C3 in normal endometria of fertile and infertile women (Tauber
et al., 1985; Bartosik et al., 1987; Isaacson et al., 1990), with
or without endometriosis.
Several studies (Komm et al., 1986; Sundstrom et al., 1989,
1990; Kuivanen et al., 1989) conducted in rats showed that the
rat uterine lining produces a 180 kDa protein recognized to be
C3 by specific antibodies and by cDNA sequencing. This rat
endometrial C3 is an oestrogen-dependent protein. Interestingly,
rat liver C3 mRNA is not up-regulated by oestrogens. An
immunohistochemical analysis of rat endometrial C3 and RNA
extractions from separated epithelial and stromal cells (Sundstrom
et al., 1989) clearly attributed the origin of rat endometrial C3
to the epithelial cells. In humans, the situation seems to be
different: stromal and epithelial cells purified from
endometriomas and cultured separately in presence of
[35S]methionine both produced radiolabelled C3, but the
epithelial cells were several times more active in C3 synthesis
(Isaacson et al., 1989). These results confirmed a previous
immunofluorescence study of C3 in normal and abnormal
endometrium (Weed and Arquembourg, 1980) showing the
presence of this complement factor in stromal as well as epithelial
cells. Finally, epithelial cell monolayers of gestational endometria
incorporate [35S]methionine into immunorecognizable
radioactive C3 (Fay et al., 1990). One can thus conclude from
the literature that normal, abnormal (endometriomas) and
gestational endometria produce C3 and that this secretion is
essentially due to the epithelial cells. None of these studies,
however, quantified the C3 contribution of the different cell types;
neither are there indications about the contamination of stromal
cell cultures by epithelial cells (which could explain a possible
in-vitro production of C3 by stromal cells). Furthermore, human
endometrium is not only composed of stromal and epithelial cells,
as numerous lymphomyeloid cells invade the endometrium at each
cycle (Bulmer et al., 1988; Vince et al., 1990) and colonize both
the stromal and epithelial compartments (Pace et al., 1991). Since
several of these leukocytes and particularly the macrophages are
known to produce complement factors, including C3 (Colten
et al., 1986), it is difficult to know if endometrial epithelial and
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stromal cells and/or endometrial leukocytes are responsible for
C3 synthesis and secretion.
The purpose of the present study was to quantify by
radioimmunoassay the C3 produced in vitro by different
endometrial cell types, including stromal, epithelial and
lymphomyeloid cells.
Materials and methods
Cell preparation and culture
Fresh samples of endometrial tissue were obtained from women
(32-46 years of age) undergoing a hysterectomy for reasons
other than malignancy (mainly for myomata) and brought to the
laboratory within 1 h of surgery. Endometria were analysed
separately by the Pathology Department and described as
proliferative (n = 5), secretory (n = 4), proliferative from
patients with mild peritoneal endometriosis (according to the
surgeon's report; n = 2) and secretory from patients bearing a
non-medicated intra-uterine device (IUD; Gravigard from GD
Searle; n = 2). Tissues were processed and stromal and glandular
cells separated and cultured as previously described (Martelli
et al., 1993). Lymphomyeloid cells in the stromal and glandular
cell suspensions were immunoadsorbed (or not) using a mouse
monoclonal antibody against human leukocyte common antigen
(anti-CD45; Dakopatts, Copenhagen, Denmark) and magnetic
particles coated with a second antibody (sheep anti-mouse IgG;
Dynabeads M 280, Dynal Milan Analytica, Roche, Switzerland)
according to a previously published protocol (Martelli et al.,
1993). Viability of the cells was assessed by the trypan blue
exclusion test and never found to be <95%. Cells (106/ml)
were cultured separately in triplicate either as purified stromal
or glandular cells (not contaminated by lymphomyeloid cells) or
as non-purified glandular or stromal cells (contaminated by
lymphomyeloid cells).
Cultures were performed as indicated (Martelli et al., 1993)
in 12-well tissue culture plates (Costar, Cambridge, MA, USA)
and incubation done at 37 °C in an atmosphere of 5% CO2 in
air in a humid incubator. Culture medium was Roswell Park
Memorial Institute (RPMI) 1640 (Gibco, Basel, Switzerland)
supplemented with 10% heat-inactivated fetal calf serum (FCS;
Amined, Birsfelden, Switzerland), penicillin G (106 IU),
200 fig/streptomycin (both from Hoechst, Darmstadt, Germany)
and 2.5 /tg/ml fugizone (Gibco); the medium was changed every
other day. In some experiments, cycloheximide (50 /tg/ml,
Sigma, St Louis, MO, USA) was added to the medium on the
second day of culture. Cell supernatants were stored at —20°C
until assayed.
Immunohistochemistry
Paraffin-embedded sections of proliferative (n = 3) and secretory
(n = 3) endometria and of one implantation site of an 11 week
pregnancy were obtained from the Pathology Department,
University of Geneva, Switzerland. These were stained with
antibodies to cytokeratin and with anti-human C3b (Jansen
Biochimica, Amined Birsfelden, Switzerland) using biotinylated
horse anti-mouse or anti-rabbit IgG followed by an avidin-biotin
peroxidase complex according to a technique already reported
(Weintraub et al., 1990). Negative controls included replacement
of the primary antibody with unrelated mouse myeloma
monoclonal antibody.
In order to assess the degree of purity of our cell preparations,
immunohistochemistry was also performed on the cell
suspensions obtained after treatment of the tissues for culture.
Briefly, before plating the stromal or the glandular cells
(immunopurified or not), aliquots of the cell suspensions were
spun on clean microscope slides in a cytocentrifuge (Shandon,
Astomore, UK). The slides were fixed in acetone, washed and
stained with 50 /tl of a 1:20 dilution of the first antibody
(monoclonal mouse anti-human) CD45, factor VUI, vimentin (all
from Dakopatts, Copenhagen, Denmark), anti-cytokeratin clones
AE1/AE3 (Boehringer Mannheim, Germany) and anti-cytokeratin
CAM 5.2 (Becton Dickinson Inotech, Basel, Switzerland). The
last two antibodies were used as a mixture (1:1) according to
a method already reported (Martelli et al., 1993). The results
were expressed as the number of positive cells per 300 total cells
counted (percentage).
Radioiodination of C3
Purified human C3 (Calbiochem, Lucerne, Switzerland) was
diluted in phosphate-buffered saline (PBS) at a final concentration
of 658 /tg/ml. Aliquots of 20 /tl (13.2 /tg) were prepared and
stored at -20°C until used for radioiodination or preparation
of the standard curve.
After thawing, a 20 /tl aliquot of C3 was radioiodinated with
the lactoperoxidase technique as modified by Aubert (1977). The
reagents were added in the following order: pure C3 (13.2 /tg
in 20 /tl PBS), sodium acetate (20 /tl, 0.4 M, pH 5.6), 1.0 mCi
of 125I (100 mCi/ml; Amersham, Zurich, Switzerland), 5 /tg
lactoperoxidase (10 /tl from a freshly prepared 0.5 mg/ml solution
in the acetate buffer) and hydrogen peroxide (10 /tl of a 1:20 000
dilution). The reaction was stopped after 30 s by the addition
of 100 /tl of transfer buffer (0.01 M phosphate, 16% sucrose,
1 % potassium iodide and 0.1 % sodium azide, pH 7.6) and the
reaction mixture transferred to a Sepharose Cl 4 B column
(60 x 1.5 cm; Pharmacia, Uppsala, Sweden) pre-equilibrated in
the assay buffer [0.05 M phosphate containing 0.5% bovine
serum albumin (BSA) pH 7.4]. Elution was carried out with the
same buffer. 125I-labelled C3 eluted as a single peak (around
fraction 30, 20 drops/fraction) that was clearly separated from
the peak of unreacted 125I (fraction 45). The fractions containing
125I-labelled C3 were pooled, aliquoted and stored at -20°C
until used.
Radioimmunoassay of C3
The assay was set up essentially as reported for another protein
(Bischof et al., 1989) with minor modifications.
Rabbit anti-human C3b (100 /tl/tube, Janssen Biochimica) at
a final dilution of 1:100 000 in the assay buffer (0.05 M phosphate
containing 0.5 % BSA, pH 7.4) was preincubated for 6 h at room
temperature with 100 /tl of standards (purified C3, 5-658 ng/ml)
or samples to be measured. After preincubation, 100 /tl of
l25I-labelled C3 (10 000 cpm) was added to each tube and
incubation continued for 16-18 h at room temperature. After
incubation, free and antibody-bound C3 were separated by adding
1 ml of immunoadsorbent (sheep anti-rabbit IgG diluted in 15%
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polyethylene glycol). After 20 min of incubation, the samples
were centrifuged, washed and counted in an LKB 1261
Multigamma (Wallac MBV, Stafa, Switzerland). The amount of
bound radioactive 125I-labelled C3 in the pellets was compared
to that obtained with the standard curve and calculated with a
computer using the RIA calc programme (Wallac) based on logit
B/Bo versus the log of the concentration of cold C3. This RIA
has a sensitivity limit of 3 ng/ml and intra- and inter-assay
coefficients of variation of 8.6 ± 2.0 and 12.4 ± 4.6% (mean
± SD) respectively. All samples including the standard curve
(eight values) were run in duplicates. Results were expressed as
ng of C3 per 106 cells in culture. Statistical analysis was




Immunohistochemical analysis performed on the cell suspensions
before plating allowed assessment of the degree of purity of our
preparations (Table I). Before immunopurification, the stromal
cell suspension was contaminated by epithelial cells (1-6%) and
by lymphomyeloid cells (12-24%). Immunopurification
eliminated all lymphomyeloid cells, but the immunopurified
stromal cell suspension was still contaminated by 1-4%
glandular and 0 -2% endothelial cells. The glandular cell
suspension was 75-92% pure after immunopurification, but was
still contaminated by 2—5% stromal and 0—2% endothelial cells.
As shown in Figure 1, in proliferative endometrium antibodies
to C3 diffusely stained the stromal and epithelial cells. The
cytoplasm but not the nuclei of these cells was slightly stained
(Figure 1 A). In contrast, staining was much more intense in the
cytoplasm of both cell types as well as in endothelial cells in a
secretory endometrium (Figure IB). Some decidual cells of the
implantation site stained positively for C3 whereas both the villous
and the extravillous trophoblastic cells (cytotrophoblastic cells
invading the decidua) were negative. Some C3 staining was,
however, visible in the fetal stroma of the trophoblastic villi
(Figure ID). Villous and extravillous trophoblast was positive
for cytokeratin whereas the decidual cells were negative
(Figure 1C).
Cultures
In endometria obtained during the proliferative or the secretory
phase or obtained from the two women bearing an IUD, the
glandular cells released significantly more (0.001 < P < 0.05)
C3 than the corresponding stromal cells. In contrast, in eutopic
endometria (n = 2) from women with peritoneal endometriosis,
the secretion of C3 by stromal cells was significantly higher
(0.001 < P < 0.03) than the corresponding epithelial cells
(Figure 2). Glandular cells from proliferative endometria released
three times more C3 than the stromal cells from the same
endometria, whereas the glandular cells from a secretory
endometrium secreted ~ 10 times more C3 than the
corresponding stromal cells (Figure 2).
When 50 /ig/ml cycloheximide was added on day 2 to the
culture medium, the release of C3 from both glandular as well
as stromal cells was significantly (0.001 < P < 0.01) inhibited
(Figure 3).
In order to compare the production rates of C3 among the
different endometria and cell types cultured, we calculated the
concentration of C3 produced over 24 h for the first 6 days of
culture (Figure 4). In proliferative, secretory and IUD-bearing
endometria, the C3 production rate was significantly (0.001 <
P < 0.05) lower in stromal as compared to epithelial cells. In
eutopic endometria of women with mild peritoneal endometriosis,
the C3 production rate was similar in stromal and glandular cells
(Figure 4). Irrespective of the type of cell, C3 production in
proliferative endometria was significantly (0.001 < P < 0.01)
lower than in secretory endometria. Endometria bearing an IUD
had a similar stromal but a significantly (P < 0.001) increased
glandular C3 production when compared to secretory phase
endometria. The stromal and glandular C3 production of eutopic
endometria of women with endometriosis was significantly higher
(P < 0.001) than in normal proliferative phase endometria
(Figure 4).
During the first 2 - 6 days of culture, the release of C3 by
immunopurified glandular and stromal cells (Figure 5, without
CD45 cells) was significantly lower (0.005 < P < 0.01) than
the release of C3 by non-immunopurified cells (Figure 5, with
CD45 cells).
This decrease did not depend on the histological phase
(proliferative, secretory, IUD or endometriosis), with one
noticeable exception: purified or non-purified glandular cells from
eutopic endometria of women with endometriosis secreted similar
amounts of C3 throughout the 20 days of culture (Figure 5). After
the 6th to 8th day of culture, immunopurified stromal cells
secreted significantly (0.001 < P < 0.01) more C3 than non-
immunopurified cells, irrespective of the type of endometrium
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Fig. 1. Immunohistochemical distribution of C3 in a proliferative (A) and a secretory endometrium (B) and of cytokeratin (C) and C3 (D)
in the implantation site of an 11 week pregnancy. Note the diffuse cytoplasmic staining in both stromal and glandular cells in A and the
intense staining in B. Cytokeratin positivity is seen in villous trophoblast and in trophoblastic cells within the decidua (C), whereas
trophoblast (villous or extravillous) is negative and some decidual cells are positive for C3 (D).
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Fig. 2. Release of C3 in vitro by cultured stromal and glandular cells. Mo =106.
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Fig. 4. Production rates of in-vitro released endometrial C3 over the first 6 days of culture of stromal and glandular cells.
1656
Origin of endometrial C3
EFFECT OF CD45 CELLS ON ENDOMETRIAL C3 PRODUCTION
PROLIFERATIVE PHASE
with CD45 cells
- without CD45 cells
10 12 0 2 4 6 10 12 14 16 18 20
PROLIFERATIVE PHASE WITH ENDOMETRIOSIS




















SECRETORY PHASE WITH IUD
8 10 12 14 16 18 20
Days of culture
0 2 4 6 8 10 12 14 16 18 20
Days of culture
Fig. 5. Effect of immunopurification on endometrial C3 release by stromal and glandular cells in vitro.
from which the cells came. The same observation was true for
glandular cells from secretory endometria bearing an IUD but
not for glandular cells of proliferative phases (normal proliferative
phase or proliferative phase with endometriosis, Figure 5).
Discussion
The present immunohistochemical study on normal endometrium
confirms two previous reports (Weed and Arquembourg, 1980;
Bartosik et al., 1987) that native C3 is present in glandular as
well as stromal cells. However, using an antibody to C3d (a split
product of C3b), none of these cells were positive for C3 (D'Cruz
and Wild, 1992), indicating that intact C3 and not its split products
is associated with the endometrial cells. Our study extends these
previous observations to an implantation site of an 11 week
pregnancy showing that decidual but not extravillous or villous
cytotrophoblastic cells are also positive for C3. Taken together,
these results indicate that C3 is present in stromal as well as
glandular cells during the different physiological states an
endometrium goes through. Since it is almost impossible on the
basis of morphological criteria to distinguish between an
endometrial stromal cell and an endometrial lymphomyeloid cell,
one cannot exclude that some C3 was associated with the
lymphomyeloid cells colonizing the uterus.
Using the procedure outlined above, the different endometrial
cells were separated and purified. The lymphomyeloid cells
represented up to 20% of the stromal cell suspension, the largest
proportion of these cells being the large granular lymphocytes
and the macrophages (Buhner et al., 1988). After immunopurifi-
cation with the anti-CD45 antibody, the stromal and the glandular
cell cultures were free of lymphomyeloid elements but were still
contaminated by 2 - 7 % of endothelial and stromal elements in
the glandular cell culture and by 1-6% of endothelial and
glandular cells in the stromal cell cultures, a result already
reported by us (Martelli et al., 1993). These observations have
to be kept in mind before attributing the in-vitro produced C3
to one cell type.
In presence of cycloheximide (50 /ig/ml), the release of C3
by stromal as well as glandular cells was inhibited, indicating
that C3 was produced by glandular and stromal cells and not only
released non-specifically. Cycloheximide was not toxic to the cells
under our culture conditions since viability checks performed on
two different cultures (after 6 and 8 days respectively) did not
demonstrate any significant fall in viability (results not shown).
These results confirm previous reports (Isaacson et al., 1989,
1990) which showed that [35S]methionine was incorporated into
immunoprecipitable C3 mainly by glandular cells but also by
stromal elements. In our hands, C3 production by glandular cell
preparations obtained from normal endometria, irrespective of
the phase of the cycle, was always higher than C3 production
by stromal cells. Furthermore, both cell types produced more
C3 during the secretory phase as compared to the proliferative
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one, but the glandular cells increased their C3 production much
more than the stromal cells. These last observations point to the
possibility that in humans, in contrast to the situation in rats,
progesterone might be a direct or an indirect (via another
endometrial factor) stimulator of endometrial C3 production. That
the production of C3 by the stromal cell is specific to this cell
and is not due to contamination by other cells is shown by (i)
stromal C3 production represents one-third to one-tenth of the
corresponding glandular cell production, a figure too high to be
explained by the 6% contamination of stromal cell culture by
glandular cells; (ii) immunopurified stromal cells, i.e. without
lymphomyeloid elements, do release significant amounts of C3.
The fact that during the first 2 - 6 days of culture the
immunopurified endometrial cells produced less C3 than the non-
immunopurified cells can be explained in two different ways:
either endometrial lymphomyeloid cells do produce C3 under in-
vitro conditions or else they produce factors (cytokines?) which
promote glandular and stromal C3 production. Furthermore, the
observation that immunopurified endometrial cells grown in vitro
for > 6 days produced more C3 than non-immunopurified cells
might be explained either by a poor survival of lymphomyeloid
cells under our culture conditions or by the secretion by
lymphomyeloid cells of factors which inhibit specifically or
unspecifically the C3 production of stromal and glandular cells.
It must be said, however, that in these long-term cultures cells
might have lost their differentiated function (particularly since
they were cultured without hormones). This complicates the
interpretation of the results. Unfortunately, no functional marker
of endometrial function is readily available to help investigate
this aspect. This is why only the first 6 days of culture were
considered in Figure 4.
The presence of an IUD in the uterine cavity has a stimulating
effect on C3 production. This production cannot be attributed
to inflammatory cells infiltrating the endometrium as a
consequence of the presence of the IUD, since the production
of C3 by immunopurified glandular and stromal cells was higher
than in the non-immunopurified cells. It is not clear by which
mechanism this stimulation of C3 occurs. Eutopic endometria
of women with mild endometriosis produce very high levels of
C3, an observation already made by others (Bartosik et al., 1987;
Isaacson et al, 1989, 1990).
Our study extends these observations by showing that this
increase is due to stromal as well as to glandular cells, with little
or no contribution of lymphomyeloid elements. What are the
factors produced by endometrial implants located in the abdominal
cavity which influence the C3 production of the uterine
endometrium? Further investigations are needed to answer this
question. However, our results clearly show that the metabolism
of the eutopic endometrium is influenced by the ectopic one.
The function of endometrial C3 can only be speculated, but
it is interesting to consider it. According to Bronson and Fusi
(1990), peptides containing the Arg-Gly-Asp (RGD) adhesion
sequence play a role in spermatozoon-oolemma adhesion. Since
C3b contains an RGD sequence (Wright et al., 1987) and since
C3 binds to acrosome-reacted spermatozoa (Anderson et al.,
1990), it could be that endometrial C3 is involved in
spermatozoon-egg interaction. Alternatively, it could also be
that endometrial C3 is split into C3a and C3b by the presence
of a blastocyst, since blastocysts produce proteases (Puistola et
al., 1989) in the uterine cavity. C3a, a well-known anaphylatoxin,
could stimulate the endometrial mast cells to release histamine,
which in turn would increase the endometrial vascular
permeability in the vicinity of the embryo.
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